First Cycle Approval Rate Tops 50% For 2006 NMEs; Merck Hits 100%
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Merck skillfully navigated FDA’s approval process in 2006, receiving all five of its new molecular entity and novel biologic approvals after only a single review cycle.
You may also be interested in...
Early Failure Is Like Yeast: Early Triage Boosts Big Pharma's R&D Productivity - Tufts
One of the strengths of the big pharma R&D model is the ability to triage candidates early in development, a recent study of R&D productivity at the top 50 pharmaceutical firms by the Tufts Center for the Study of Drug Development suggests.
Early Failure Is Like Yeast: Early Triage Boosts Big Pharma's R&D Productivity - Tufts
One of the strengths of the big pharma R&D model is the ability to triage candidates early in development, a recent study of R&D productivity at the top 50 pharmaceutical firms by the Tufts Center for the Study of Drug Development suggests.
FDA First Cycle Approval Rate Is Silver Lining In Cloud Of Dismal NME Count
Three-quarters of the new molecular entities cleared by FDA in 2007 were approved on the first review cycle, a high for this decade and a positive note to counterbalance the record low number of NMEs approved.